Wide Ranks

LAB

Standard BioTools Inc.

1.82

Top Statistics
Market Cap 677 M Forward PE -11.74 Revenue Growth -14.20 %
Current Ratio 3.76 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -79.92 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.95 Enterprise / Revenue 1.43 Price To Sales Trailing12 Months 4.35
Profitability
Profit Margins -79.92 % Operating Margins -29.42 %
Balance Sheet
Total Cash 28 M Total Cash Per Share 0.3710 Total Debt 111 M
Total Debt To Equity 118.03 Current Ratio 3.76 Book Value Per Share 1.23
All Measures
Short Ratio 650.00 % Message Board Id finmb_742365 Fax 650 871 7152
Shares Short Prior Month 21 M Return On Equity -0.3725 City South San Francisco
Uuid a18771cf-7e18-3cdf-9dad-769d494bafef Previous Close 1.71 First Trade Date Epoch Utc 1 B
Book Value 1.23 Beta 1.57 Total Debt 111 M
Volume 1 M Price To Book 1.47 Fifty Two Week Low 1.21
Total Cash Per Share 0.3710 Total Revenue 155 M Shares Short Previous Month Date 1 B
Target Median Price 2.75 Audit Risk 5 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -29.42 % Target Mean Price 3.08
Net Income To Common -170603008 Short Percent Of Float 0.0810 Implied Shares Outstanding 372 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M
Average Volume10days 2 M Total Cash 28 M Next Fiscal Year End 1 B
Revenue Per Share 0.5580 Held Percent Insiders 0.0193 Ebitda Margins -73.32 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 9 Regular Market Previous Close 1.71 Target Low Price 2.50
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.85 Open 1.72
Free Cashflow -66162752 State CA Dividend Yield 0.00 %
Return On Assets -0.1469 Time Zone Short Name EST Board Risk 8
Trailing Eps -0.6900 Day Low 1.72 Address1 2 Tower Place
Shares Outstanding 372 M Compensation Risk 10 Price Hint 4
Target High Price 4.00 Website https://www.standardbio.com 52 Week Change -0.2946
Average Volume 1 M Forward Eps -0.2200 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 333.00 % Is_sp_500 False
Regular Market Day High 1.86 Profit Margins -79.92 % Debt To Equity 118.03
Fifty Two Week High 3.04 Day High 1.86 Shares Short 14 M
Regular Market Open 1.72 Industry Key medical-devices Earnings Growth 0.00 %
Enterprise To Revenue 1.43 Revenue Growth -14.20 % Shares Percent Shares Out 0.0394
Operating Cashflow -143456000 Currency USD Time Zone Full Name America/New_York
Market Cap 677 M Is_nasdaq_100 False Zip 94080
Quote Type EQUITY Industry Medical Devices Long Name Standard BioTools Inc.
Overall Risk 9 Regular Market Day Low 1.72 Held Percent Institutions 0.7332
Current Price 1.82 Address2 Suite 2000 Enterprise To Ebitda -1.95
Financial Currency USD Current Ratio 3.76 Gross Margins 48.56 %
Industry Disp Medical Devices Number Of Analyst Opinions 3 Country United States
Float Shares 48 M Two Hundred Day Average 2.18 Governance Epoch Date 1 B
Enterprise Value 222 M Price To Sales Trailing12 Months 4.35 Forward PE -11.74
Regular Market Volume 1 M Ebitda -114313000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific.

It operates through two segments: Proteomics and Genomics.

The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.

It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats.

In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs.

It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations.

It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022.

Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.